Companies · RGEN
Repligen
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 6, 2026
Repligen Issues $1.0B Convertible Notes, Exchanges Maturing 2028 Debt for Lower-Cost 2031 Obligations
Repligen completed a dual financing transaction on November 6, 2026, issuing $1.0 billion in aggregate principal of 0.25% Convertible Senior Notes due 2031. The transaction consisted of $541.4 million exchanged from maturing 1.00% Convertible Senior Notes due 2028 and $458.6 million in cash subscription. The refinancing reduces the coupon rate from 1.00% to 0.25% and extends maturity by three years, with an initial conversion price of $226.37 per share (20% premium to the October 29 closing price of $188.64). This capital structure move improves debt servicing costs while maintaining conversion optionality for investors.
Tone: neutralRevenue
$738.3M
RGEN 10-K · FY 2025
Employees
2,000
Revenue FY2024
$634.4M
Founded
1981
Profile
RGEN 10-K Item 1 · Feb 26, 2026Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biological drugs, including monoclonal antibodies, cell and gene therapies, and RNA-based therapeutics. The company operates as a single bioprocessing segment with four product franchises — Filtration, Chromatography, Process Analytics, and Proteins — serving biopharmaceutical companies and CDMOs worldwide. Its portfolio spans consumables, hardware, and integrated solutions across upstream and downstream manufacturing processes.
Read filing description ↓ Collapse description ↑
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. As the overall market for biologics continues to grow and expand, our primary customers – global biopharmaceutical companies, contract development and manufacturing organizations and other life science companies (integrators) – face critical production cost, capacity, quality and time pressures. Built to address these concerns, our products help set new standards for the way biologics are manufactured. We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies ('mAbs') and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines and cell and gene therapies ('C>') – that are improving human health worldwide. We currently operate as one bioprocessing business, with a comprehensive suite of products to serve both upstream and downstream processes in biological drug manufacturing. Building on over 40 years of industry expertise, we have developed a broad and diversified product portfolio that reflects our passion for innovation and the customer-first culture that drives our entire organization. We continue to capitalize on opportunities to maximize the value of our product platform through both organic growth initiatives (internal innovation and commercial leverage) and targeted acquisitions. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. A majority of our 19 manufacturing sites are located in the United States (including California, Massachusetts, New Hampshire, New Jersey and New York). Outside the United States, we have manufacturing sites in Estonia, France, Germany, Ireland, the Netherlands, Sweden, and Taiwan.
Primary products
- XCell ATF Cell Retention Systems
- Flat Sheet Cassettes (TangenX)
- Hollow Fiber Consumables
- KrosFlo TFF Systems
- Fluid Management (bags, tubing, valves, totes, carts, mixers, ProConnex flowpaths)
- OPUS Pre-Packed Columns
Business segments
End markets
Geographies
Named customers
There was no revenue from customers that represented 10% or more of the Company's total revenue for the years ended December 31, 2025, 2024 and 2023.
Named competitors
“We compete with several medium and small companies in each of our product categories as well as several large companies, including Danaher Corporation (Cytiva), Thermo Fisher Scientific Inc., MilliporeSigma and Sartorius.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total revenue increased from $634.4 million in 2024 to $738.3 million in 2025, driven primarily by product revenue growth across the bioprocessing portfolio including contribution from the 908 Devices PAT Portfolio acquisition.
The rest of RGEN is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.